Main Menu
Evrys Bio
3805 Old Easton Road
Doylestown, PA 18902
+1 215 249 7883
For Media and Investor Inquires:
[email protected]
For Business Development Inquires:
[email protected]
3805 Old Easton Road
Doylestown, PA 18902
+1 215 249 7883
For Media and Investor Inquires:
[email protected]
For Business Development Inquires:
[email protected]
IBC Minutes 03.11.26
UncategorizedVIDEO – Inc. Names Lillian Chiang to Its 2026 Female Founders List
UncategorizedInc Adds Lillian Chiang to Its 2026 Female Founders 500 List
UncategorizedEvrys Bio to Present at the H.C. Wainwright Liver Disease Virtual Conference
UncategorizedStructural basis for sirtuin 2 activity and modulation: Current state and opportunities
UncategorizedCBDS&T meeting December 2024 Ft. Lauderdale
UncategorizedDrugs Targeting Sirtuin 2 Exhibit Broad-Spectrum Anti-Infective Activity
UncategorizedAn allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity
UncategorizedLillian Chiang, CEO, presents at BioCentury Conference
UncategorizedLillian Chiang, Evrys Bio’s CEO, presents at BioCentury’s East-West Biopharma Summit October 2-4 in Boston https://conferences.biocentury.com/east-west-summit
Lou Kassa, CEO of the Hepatitis B Foundation, Blumberg Institute & Pennsylvania Biotechnology Center (PABC), talks with Dr. Lillian Chiang, CEO of Evrys Bio
News, UncategorizedListen Here: https://www.buzzsprout.com/2098231/13449574
Evrys SIRT2 Modulator Promotes Death of HCMV-Infected Monocytes, August 2023”.
News, UncategorizedEvrys SIRT2 Allosteric Modulator with Broad-Spectrum Antiviral Activity, June 2023”.
News, UncategorizedJuly 2022 EBV meeting
UncategorizedProprietary Sirtuin-2 Modulator reduces Hepatitis B Virus infectivity
UncategorizedNIAID Antiviral Summit Report
UncategorizedEvrys Bio Awarded $34 Million from DOD to Develop a Single Drug Simultaneously Effective Against Multiple Lethal Viruses
UncategorizedEvrys Bio Joins the Call to Arms
UncategorizedWhat are the features of the new Covid-19/SARS-CoV-2 strain (named lineage B.1.1.7)?
UncategorizedThe Concern: Many news reports are highlighting a novel strain of the virus causing Covid-19 and there seems to be a lot of drama created as flights to and from the UK are being cancelled. What’s lacking from these reports is information about this strain and why should there be so much concern about it. […]
The Beginninng of the End of the Pandemic Era
UncategorizedThe global scientific and technical response to the Covid-19 pandemic illustrates the power of 21st century medical science and technology. Clearly, a goal, based upon that we’ve learned, can be and should be the elimination of future pandemics. While Evrys Bio’s daily work is on the development of therapeutics for a broad range of viral […]
Advancing new tools for infectious diseases: Therapeutics and vaccine development for infectious diseases could be transformed
UncategorizedTherapeutics and vaccine development for infectious diseases could be transformed according to Viewpoint published in Science this week by Rajesh Gupta (SCIENCE20 NOV 2020 : 913-914)* Please read the whole article for a look a modern approach to infectious diseases here: SCIENCE 20 NOV 2020
Broad-Spectrum Antiviral Agents: A Crucial Pandemic Tool
UncategorizedAmesh Adaljaa of the Center for Health Security, Johns Hopkins Bloomberg School of Public Health and Thomas Inglesby of the Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA wrote a editorial in EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2019, VOL. 17, NO. 7, 467–470) spelling out the need […]
Evrys Bio’s CEO Lillian Chiang to address NIH SARS-CoV-2 Antiviral Therapeutics Summit
UncategorizedEvrys Bio’s CEO Lillian Chiang will address the topic “Are there broad spectrum modalities for targeting SARS-CoV-2 that could be useful against other viruses and thus for future pandemic response?” at the upcoming NIH Symposium scheduled for Friday, November 6, 2020 11:00 AM – 3:30 PM Eastern Time
Inhibition of Sirtuins is Broadly Effective Against Coronaviruses
UncategorizedOn October 7, 2020, staff scientist Dr. Liudi Tang presented at the Special isirv-AVG Virtual Conference on ‘Therapeutics for COVID-19’ . Dr. Tang will present the most recent data for one of Evrys Bio’s drug leads which has been demonstrated to have a broad spectrum of activities against a variety of viruses involved in human […]
Evrys Bio’s CEO Chiang presents at upcoming Bio-NJ virtual conference
UncategorizedTuesday, October 6 and Wednesday, October 7, Evrys Bio will be represented at the premier mid-Atlantic biotech and pharmaceutical partnering conference. Dr. Lillian Chiang, CEO and Dana Fowlkes, CBO will be representing Evrys Bio. This virtual conference has been extended to a total of four days to permit more opportunities for one on one partnering […]
Gov. Wolf awards $1.1 million to biotech center in Buckingham for COVID-19 work
UncategorizedPennsylvania Biotechnology Center of Bucks County is once again in the spotlight, this time as the recipient of more than $1 million in state grants to help with research in pursuing a treatment and vaccine for COVID-19. Of 23 state awards, the biotechnology center, located next to the Doylestown Airport in Buckingham, received four grants, bringing in $1.1 million […]
Pennsylvania Awards $10 Million to 23 Entities
UncategorizedGovernor Tom Wolf announced that 23 awardees will receive $10 million in grant funding through the COVID-19 Vaccines, Treatments and Therapies (CV-VTT) program to support the rapid advancement of vaccines, treatments and therapies by qualified biotechnology entities in response to the COVID-19 pandemic. Evrys Bio was awarded over $300,000 to develop treatments for virus caused […]
Evrys Bio awarded a supplement to its NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections”
UncategorizedJuly 22, 2020: In response to emergency research funding for COVID-19, the supplement extends testing of Evrys broad-spectrum antivirals to coronaviruses including SRAS-CoV-2. ABSTRACT
November 21, 2019 – Evrys Bio President & CEO, Lillian Chiang gives oral presentation, “Host Sirtuin-2 Protein (SIRT2) – A Validated Target for Broadly-Effective Antiviral Small-Molecule Drugs”
UncategorizedNovember 21, 2019 – Evrys Bio President & CEO, Lillian Chiang gives oral presentation, “Host Sirtuin-2 Protein (SIRT2) – A Validated Target for Broadly-Effective Antiviral Small-Molecule Drugs,” at the 2019 Chemical and Biological Defense Science & Technology (CBD S&T) Conference Cincinnati, OH. See the PowerPoint Presentation
July 31, 2019 – Evrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease
UncategorizedEvrys Bio awarded Phase II SBIR grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (5R44AI11407902). Details are HERE